目的:探讨急性期基因背景不明的轻型非心源性脑梗死患者行替格瑞洛或氯吡格雷抗血小板治疗的价值,为临床更高效、精准治疗提供参考。方法:选取新疆生产建设兵团第六师医院2022年1月至2023年6月收治的150例基因不明的急性轻型非心源性脑...目的:探讨急性期基因背景不明的轻型非心源性脑梗死患者行替格瑞洛或氯吡格雷抗血小板治疗的价值,为临床更高效、精准治疗提供参考。方法:选取新疆生产建设兵团第六师医院2022年1月至2023年6月收治的150例基因不明的急性轻型非心源性脑梗死患者为研究对象,充分向患者及(或)其家属说明各治疗方案下,采用随机数字表法分为A组、B组与C组,观察与比较每组患者美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分、Barthel指数量表(Barthel index,BI)评分变化情况,并统计患者不良反应发生情况与复发率。结果:三组治疗21d、90d后的NIHSS、BI评分对比差异无统计学意义(P>0.05)。治疗90d后随访,三组出血发生率、消化道不良反应发生率对比差异无统计学意义(P>0.05);A组、C组脑梗死复发率(2.00%、4.00%)相当(P>0.05),但均低于B组(P<0.05)。结论:替格瑞洛联合阿司匹林双抗方案可绕行CYP2C19基因缺陷,在治疗急性轻型非心源性脑梗死中,与传统氯吡格雷双抗对改善患者神经与日常生活功能效果相当,但能更有效地预防90d内脑梗死复发,在基因背景不明下,疗效更具优势。展开更多
Objective To investigate the impact of CYP2C19 gene polymorphism on clopidogrel reactivity and its association with longterm clinical outcome in patients with coronary heart disease(CHD)undergoing percutaneous coronar...Objective To investigate the impact of CYP2C19 gene polymorphism on clopidogrel reactivity and its association with longterm clinical outcome in patients with coronary heart disease(CHD)undergoing percutaneous coronary intervention(PCI).Methods In total,675 patients were enrolled.Based on the platelet inhibition rate,patients were categorized into two groups:clopidogrel low responsiveness(CLR)and normal clopidogrel responsiveness(NCR).The CLR group was divided into ticagrelor and clopidogrel group based on the antiplatelet drugs used in the follow-up treatment.Patients were classified into three groups(normal metabolizer,intermediate metabolizer,and poor metabolizer)based on the CYP2C19 genotype.We aimed to evaluate the impact of CYP2C19 gene polymorphism on clopidogrel reactivity.The cumulative rates of 12-month all-cause deaths,major adverse cardiovascular events(MACCEs),and bleeding events were calculated.Results CLR was observed in 44.4%of the overall population.Significant differences were observed in the platelet inhibition rate of clopidogrel among the three metabolic genotypes(P<0.05).At the 12-month follow-up,13 patients(1.9%)died and 96 patients(14.2%)experienced MACCEs.Patients with CLR(9.6%vs.11.7%vs.22.1%,P<0.05)or poor metabolizer(10.7%vs.16.4%vs.22.6%,P=0.026)experienced a higher rate of MACCEs.A MACCEs risk score between zero and two was calculated.The highest incidence of MACCEs significantly increased with the 2-positive results,and the area under the curve(AUC)was 0.712(95%CI:0.650-0.774,P<0.05).There was no significant difference between the group with a score of one and the occurrence of MACCEs(P>0.05).Conclusions Low response to clopidogrel in CHD patients is correlated with CYP2C19 gene polymorphism.CYP2C19 genotyping combined with platelet reactivity is an independent predictor of 12-months MACCEs in patients with clopidogrel treatment after PCI,which is better than either test alone.展开更多
文摘目的:探讨急性期基因背景不明的轻型非心源性脑梗死患者行替格瑞洛或氯吡格雷抗血小板治疗的价值,为临床更高效、精准治疗提供参考。方法:选取新疆生产建设兵团第六师医院2022年1月至2023年6月收治的150例基因不明的急性轻型非心源性脑梗死患者为研究对象,充分向患者及(或)其家属说明各治疗方案下,采用随机数字表法分为A组、B组与C组,观察与比较每组患者美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分、Barthel指数量表(Barthel index,BI)评分变化情况,并统计患者不良反应发生情况与复发率。结果:三组治疗21d、90d后的NIHSS、BI评分对比差异无统计学意义(P>0.05)。治疗90d后随访,三组出血发生率、消化道不良反应发生率对比差异无统计学意义(P>0.05);A组、C组脑梗死复发率(2.00%、4.00%)相当(P>0.05),但均低于B组(P<0.05)。结论:替格瑞洛联合阿司匹林双抗方案可绕行CYP2C19基因缺陷,在治疗急性轻型非心源性脑梗死中,与传统氯吡格雷双抗对改善患者神经与日常生活功能效果相当,但能更有效地预防90d内脑梗死复发,在基因背景不明下,疗效更具优势。
基金supported by the National Natural Science Foundation of China(No.62172288).
文摘Objective To investigate the impact of CYP2C19 gene polymorphism on clopidogrel reactivity and its association with longterm clinical outcome in patients with coronary heart disease(CHD)undergoing percutaneous coronary intervention(PCI).Methods In total,675 patients were enrolled.Based on the platelet inhibition rate,patients were categorized into two groups:clopidogrel low responsiveness(CLR)and normal clopidogrel responsiveness(NCR).The CLR group was divided into ticagrelor and clopidogrel group based on the antiplatelet drugs used in the follow-up treatment.Patients were classified into three groups(normal metabolizer,intermediate metabolizer,and poor metabolizer)based on the CYP2C19 genotype.We aimed to evaluate the impact of CYP2C19 gene polymorphism on clopidogrel reactivity.The cumulative rates of 12-month all-cause deaths,major adverse cardiovascular events(MACCEs),and bleeding events were calculated.Results CLR was observed in 44.4%of the overall population.Significant differences were observed in the platelet inhibition rate of clopidogrel among the three metabolic genotypes(P<0.05).At the 12-month follow-up,13 patients(1.9%)died and 96 patients(14.2%)experienced MACCEs.Patients with CLR(9.6%vs.11.7%vs.22.1%,P<0.05)or poor metabolizer(10.7%vs.16.4%vs.22.6%,P=0.026)experienced a higher rate of MACCEs.A MACCEs risk score between zero and two was calculated.The highest incidence of MACCEs significantly increased with the 2-positive results,and the area under the curve(AUC)was 0.712(95%CI:0.650-0.774,P<0.05).There was no significant difference between the group with a score of one and the occurrence of MACCEs(P>0.05).Conclusions Low response to clopidogrel in CHD patients is correlated with CYP2C19 gene polymorphism.CYP2C19 genotyping combined with platelet reactivity is an independent predictor of 12-months MACCEs in patients with clopidogrel treatment after PCI,which is better than either test alone.
